Proficio Capital Partners LLC Purchases New Shares in Regeneron Pharmaceuticals, Inc. $REGN

Proficio Capital Partners LLC acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 2nd quarter, HoldingsChannel reports. The fund acquired 909 shares of the biopharmaceutical company’s stock, valued at approximately $567,000.

Several other institutional investors have also modified their holdings of REGN. SHP Wealth Management acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $26,000. Western Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter worth about $26,000. Titan Wealth CI Ltd purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $29,000. Mowery & Schoenfeld Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $29,000. Finally, Trust Co. of Vermont acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $29,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron announced completion of a Phase 1/2 study evaluating its cemiplimab combination with SNS-101. The update keeps attention on potential pipeline progress, although the reports did not provide efficacy results or a regulatory timeline. Regeneron’s Cemiplimab Combo Trial With SNS-101 Reaches Completion
• Neutral Sentiment: A market analysis projects long-term growth in the complement-inhibitors market and lists Regeneron among leading participants. This is a broad industry forecast rather than a company-specific catalyst. 2026 Complement Inhibitors Market Analysis Report
• Neutral Sentiment: Analysts remain moderately optimistic about Regeneron, and the stock has outperformed the broader healthcare sector. The company’s recent earnings beat and double-digit revenue growth also support sentiment, though these factors were not new disclosures in the latest reports. Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector?
• Negative Sentiment: Multiple law firms—including Hagens Berman, Faruqi & Faruqi, Bronstein Gewirtz & Grossman, Levi & Korsinsky, Bernstein Liebhard, Pomerantz, Portnoy and SueWallSt—are publicizing the same securities class action and a September 14, 2026 lead-plaintiff deadline. The complaints allege Regeneron misrepresented the risks and clinical differentiation of the Phase 3 Fianlimab-Libtayo study, including slowing event accrual and a protocol amendment that allegedly increased the risk of missing the primary endpoint. The repeated notices heighten legal and reputational risk, although they do not represent separate lawsuits or establish wrongdoing. REGN Deadline Alert

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $852.03 on Thursday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $541.00 and a 1 year high of $854.49. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The firm has a market capitalization of $87.72 billion, a PE ratio of 21.06, a price-to-earnings-growth ratio of 1.61 and a beta of 0.19. The business has a 50 day simple moving average of $729.93 and a 200-day simple moving average of $719.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $12.81 earnings per share. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were issued a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.29%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. HSBC decreased their target price on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Guggenheim increased their price objective on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Piper Sandler decreased their price objective on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a report on Thursday, July 9th. Citigroup lifted their target price on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. Finally, Benchmark raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a report on Tuesday, July 7th. Fourteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $800.36.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the transaction, the director owned 17,303 shares in the company, valued at $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 1,400 shares of company stock worth $1,090,030. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.